Cannabics Pharmaceuticals, Inc. (CNBX)


Cannabics Pharmaceuticals, Inc is a biotech company that produces proprietary technologies for medical cannabis therapies.

The company’s flagship product is the Cannabics SR, a sustained release cannabis capsule to provide palliative care to cancer patients. Using a patented formulation, Cannabics SR capsules contain a pure concentrate of cannabinoids from cannabis strains which the company itself selects and breeds. Each capsule is designed to provide 10-12 hours of therapeutic effects, thus allowing for a once-a-day dosage.

Other products in the company’s line are Cannabics IN, a capsule for dry powder inhalers, and Cannabics VP, a condensed pill for standard vaporizers. As of 2013, the company’s products are circulating through five Israel hospitals. It is noted that Israel permits medical marijuana use for patients with cancer and pain-related illnesses.

Cannabics Pharmaceuticals is based in Bethesda, Maryland. According to the company website, it is developing advanced cannabinoid-based therapies through its research and development arm in Israel. It is also collaborating with medical centers in Israel, the US (including states like Colorado and California), and Europe (including countries like Spain, Czech Republic, and the Netherlands) to launch clinical studies on their products.

Cannabics Pharmaceuticals, Inc is a fairly new name in the marijuana industry. It is a subsidiary of Cannabics, Inc, which was founded in 2012 by researchers in molecular biology, pharmacology, and cancer research. The pharmaceuticals company was also formerly known as Thrust Energy Corp until 2011, and as American Mining Corporation just until June 2014.

The company is currently traded in OTC markets as CNBX, with a market cap of USD 32.7 M. Its key executives are Dr. Zohar Koren, Co-founder and CEO; Dr. Eyal Ballan, Co-founder and CTO; and Itamar Borochov, VP of Marketing.

[hungryfeed max_items=”5″ template=”1″ url=”feed://”]